Healthcare Innovation

Subscribe

Biotech and medical innovation leaders

Next Rebalance: 2026-07-01
Portfolio Metrics
Total Return
--
Sharpe Ratio
--
Max Drawdown
--
Risk Level
--
Current Holdings
Loading holdings...
Rebalance History

Apr 1, 2026

0 4 0
JNJ, LLY, MRK +1 more

New Positions

JNJ 0.0% 25.0%
LLY 0.0% 25.0%
Eli Lilly's near-term outlook is positive, driven by strong GLP-1 momentum and pipeline advancements. The upcoming US la... Eli Lilly's near-term outlook is positive, driven by strong GLP-1 momentum and pipeline advancements. The upcoming US launch of oral orforglipron in Q2 2026 is a major catalyst, potentially expanding the market and defending its ~60% share against Novo Nordisk's new oral Wegovy. [🔗](https://cognitmarket.com/article/76ed51bc/will-policy-shifts-accelerate-demand-for-eli-lilly) Positive trial data for Taltz+Zepbound and retatrutide, plus strategic acquisitions in neuroscience (Centessa) and AI (Insilico), reinforce innovation beyond GLP-1s. [🔗](https://cognitmarket.com/article/dae37e61/eli-lilly-reaches-2-75-billion-deal-with-insilico) While one analyst cites pricing pressure risks, this is offset by expanding Medicare access and employer programs. [🔗](https://cognitmarket.com/article/0a34e88b/why-one-analyst-thinks-lly-is-worth-850-while-the)
MRK 0.0% 25.0%
NVO 0.0% 25.0%